Literature DB >> 7613130

Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis.

E Masini1, L Mugnai, M Foschi, G Laffi, P Gentilini, P F Mannaioni.   

Abstract

Superoxide (O2-) and nitric oxide (NO) production by polymorphonuclear leukocyte (PMNs) and monocytes in patients with liver cirrhosis were evaluated. PMNs obtained from cirrhotic patients were less effective than those from controls in producing O2- after stimulation with opsonized zymosan, while they were more effective in producing NO, as shown by the inhibition of platelet aggregation and by the increase in cGMP content. NO synthase activity was higher in leukocytes from cirrhotic patients than in controls. A correlation was found between the cardiac index and the observed changes in the inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613130     DOI: 10.1159/000236975

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection.

Authors:  T Bruns; J Peter; S Hagel; A Herrmann; A Stallmach
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

Review 2.  Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids.

Authors:  Ikuo Nakamura
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 3.  Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review.

Authors:  J B Weinberg
Journal:  Mol Med       Date:  1998-09       Impact factor: 6.354

4.  Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes.

Authors:  Jack Peter; Oliver Frey; Andreas Stallmach; Tony Bruns
Journal:  BMC Gastroenterol       Date:  2013-02-27       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.